



Vascular Quality Initiative

Powered by m2s

College of Medicine
Department of Surgery
Division of Vascular Surgery and Endovascular Therapy

Health Science Center
PO Box 100128
Gainesville, FL 32610
(352) 273-5484 phone
(352) 273-5515 fax

Date: _____

Dear _____,

We had the pleasure of seeing _____ in our office recently in consultation. He/she has a history of Peripheral Vascular Disease (PVD). As you know, PVD is linked to other adverse cardiovascular events, and there are a number of risk factor modification measures that have been demonstrated by a growing body of literature to improve the long-term outcomes of these patients.

Our group is an active participant in The Society for Vascular Surgery's Vascular Quality Initiative (SVS VQI), which actively promotes risk factor modification measures including such things as, smoking cessation, exercise regimens, statin therapy, anti-platelet therapy, and control of hypertension, in patients undergoing vascular procedures.

In preparation for a vascular intervention, we may have started new medications on our mutual patient, and we wanted to make sure that you are aware. If he/she has been started on a new medication, and you have no objections, please make arrangements for the appropriate clinical follow-up, which we would like to defer to you as the primary provider.

New medications started (circled):

Statin^{1,2,3}

ACE Inhibitor/ARB⁴

Anti-platelet therapy⁵

Thank you very much for your consideration and continued care of our shared patient. Please do not hesitate to contact our office at 352-273-5484 if you have any questions.

Sincerely,

¹ De Martino RR, Hoel AW, Beck AW, Eldrup-Jorgensen J, Hallett JW, Upchurch GR, Cronenwett JL, Goodney PP; Vascular Quality Initiative. *Participation in the Vascular Quality Initiative is associated with improved perioperative medication use, which is associated with longer patient survival.* J Vasc Surg. 2015 Apr;61(4):1010-9

² Stalenhoef AF. *The Benefit of Statins in Non-Cardiac Vascular Surgery Patients.* J Vasc Surgery 2009; 49:260-5.

³ Paraskevas, KI. et. al. *Statins and Noncardiac Vascular Disease.* Current Opinion in Cardiology; 27(4), July 2012 p. 392-397.

⁴ Massachusetts Medical Society. *Effects of an Angiotension-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients.* The New England Journal of Medicine. 2000: Volume 342, Number 3, p. 145-153.

⁵ Rooke, Thom W. et. al. *2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients with Peripheral Artery Disease (Updating the 2005 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.* Circulation. 2011; 124:3030-2045.